TYK Medicines' (HKG:2410) loss attributable to owners narrowed to 299.8 million yuan for 2025, from 387 million yuan a year earlier, according to a Monday Hong Kong bourse filing.
Shares of the pharmaceutical company were up nearly 2% in late morning trade on Tuesday.
Loss per share shrank to 0.80 yuan from 1.15 yuan a year earlier.
The company did not generate revenue in 2025. In 2024, its revenue came in at 107,000 yuan.